You're 100% right Zoom. A few things that really
Post# of 30027
(Total Views: 643)
Posted On: 05/11/2018 8:08:05 PM
You're 100% right Zoom.
A few things that really stood out to me in terms of being news...
Based upon an independent 3rd party valuation of the PD-LID indication the US & Europe alone has a robust 9-figure valuation....
(A robust 9 figure for 1 indication for 2 areas? US and Europe only.
That's massive NEWS to me.
Wonder what the valuation would be including All of Asia, HK, China, Japan & Australia. And what would it come in at with secondary indications such as Agitation in Alzheimer's disease and Adult ADHD...)
$100,000,000 is the lowest 9 figure number. I'm curious as to what Robust means.
The Company has begun working with domestic (NYSE or NASDAQ) and international advisors (Hong Kong, or others) to determine the best jurisdiction to list Elto Pharma.
(They've already begun is NEWS to me)
We believe that capital raising around Elto Pharma could drive the value of the Amarantus shares, based upon our then ownership position in that entity.
(So, AMBS may not have complete ownership in ELTOP PHARMA? Wonder how much and who else would own shares? All NEWS to me)
https://m.investorshangout.com/post/viewall?id=58310
Speaking of news, this was in the news a couple days ago.
Hong Kong exchange to accept listing applications under new rules from April 30, chief says
Charles Li Xiaojia says results of a consultation into reform of listing rules to be announced on April 24
Enoch YiuUPDATED : Friday, 20 Apr 2018, 11:38PM
Companies with dual-class shareholding structures and biotech firms with no revenue will be able to apply for listing on the Hong Kong stock exchange from April 30 under new bourse rules, the head of the exchange said on Friday.
Hong Kong Exchanges and Clearing (HKEX) chief executive Charles Li Xiaojia told a forum on Friday that the results of a consultation into reform of the bourse’s listing rules would be announced on April 24, with the new rules “becoming effective the Monday after”.
The exchange has been planning a major overhaul of its listing rules as it tries to catch up with New York and Shanghai and others in the race to be the world’s largest market for initial public offers. It has previously not allowed listings by companies with dual-class share structures, making it less attractive to big technology firms, many of which use such governance forms.
“This will be the largest listing reform in Hong Kong for 25 years,” Li said, noting that companies with different classes of shares often took their listings to the US instead.
“After the reform, it will change the regulatory landscape. I am comfortable Hong Kong will be able to attract these companies to list here,” he said.
When the new rules go into effect, biotech firms that have yet to generate revenue, as well as Chinese technology companies seeking secondary listings in Hong Kong, would also be able to apply for listings, Li said. He has previously said the exchange had set a goal of overtaking the Nasdaq market within five years in terms of the number of listings of mainland Chinese biotechnology firms.
Hong Kong plans to overtake Nasdaq as listing destination of choice for Chinese biotech firms
He expressed confidence that big name companies reportedly seeking listings, including Chinese mobile phone maker Xiaomi, oil company Saudi Aramco and Chinese online payment firm Ant Financial, would list in Hong Kong, and did not see plans by China to create China depositary receipts (CDRs), similar to American depositary receipts, to lure tech firms home as a threat to Hong Kong.
“According to my understanding, Ant Financial does not have a weighted voting right structure, so it is qualified to list A shares in China and H shares in Hong Kong,” he added.
Ant Financial is an affiliate of Chinese e-commerce giant Alibaba, which decided in 2014 to list in the US and not Hong Kong, where its dual-class share structure was not accepted at the time. The loss of the listing – worth US$25 billion – was the spark for debate in Hong Kong over listing rules.
Li said Alibaba could now apply for a secondary listing in Hong Kong, something the company’s founder, Jack Ma Yun, said in January he would “seriously consider”.
Jack Ma to consider listing Alibaba on Hong Kong stock exchange
Even if Alibaba opted for a CDR listing in mainland China, it would be an advantage if it also listed in Hong Kong, Li said, because Chinese investors could trade the physical stock directly via the Stock Connect scheme that links mainland and Hong Kong bourses, while international investors could arbitrage on the price differences between the US and Hong Kong listed stocks.
Li also saw Xiaomi as taking a similar tack, listing in Hong Kong as well issuing CDRs in mainland China.
Wall Street cheers Hong Kong’s IPO rules revamp but sees New York’s dominance unthreatened
Full Article....
https://www.google.com/amp/m.scmp.com/busines...les%3famp=
Aloha
A few things that really stood out to me in terms of being news...
Based upon an independent 3rd party valuation of the PD-LID indication the US & Europe alone has a robust 9-figure valuation....
(A robust 9 figure for 1 indication for 2 areas? US and Europe only.
That's massive NEWS to me.
Wonder what the valuation would be including All of Asia, HK, China, Japan & Australia. And what would it come in at with secondary indications such as Agitation in Alzheimer's disease and Adult ADHD...)
$100,000,000 is the lowest 9 figure number. I'm curious as to what Robust means.
The Company has begun working with domestic (NYSE or NASDAQ) and international advisors (Hong Kong, or others) to determine the best jurisdiction to list Elto Pharma.
(They've already begun is NEWS to me)
We believe that capital raising around Elto Pharma could drive the value of the Amarantus shares, based upon our then ownership position in that entity.
(So, AMBS may not have complete ownership in ELTOP PHARMA? Wonder how much and who else would own shares? All NEWS to me)
https://m.investorshangout.com/post/viewall?id=58310
Speaking of news, this was in the news a couple days ago.
Hong Kong exchange to accept listing applications under new rules from April 30, chief says
Charles Li Xiaojia says results of a consultation into reform of listing rules to be announced on April 24
Enoch YiuUPDATED : Friday, 20 Apr 2018, 11:38PM
Companies with dual-class shareholding structures and biotech firms with no revenue will be able to apply for listing on the Hong Kong stock exchange from April 30 under new bourse rules, the head of the exchange said on Friday.
Hong Kong Exchanges and Clearing (HKEX) chief executive Charles Li Xiaojia told a forum on Friday that the results of a consultation into reform of the bourse’s listing rules would be announced on April 24, with the new rules “becoming effective the Monday after”.
The exchange has been planning a major overhaul of its listing rules as it tries to catch up with New York and Shanghai and others in the race to be the world’s largest market for initial public offers. It has previously not allowed listings by companies with dual-class share structures, making it less attractive to big technology firms, many of which use such governance forms.
“This will be the largest listing reform in Hong Kong for 25 years,” Li said, noting that companies with different classes of shares often took their listings to the US instead.
“After the reform, it will change the regulatory landscape. I am comfortable Hong Kong will be able to attract these companies to list here,” he said.
When the new rules go into effect, biotech firms that have yet to generate revenue, as well as Chinese technology companies seeking secondary listings in Hong Kong, would also be able to apply for listings, Li said. He has previously said the exchange had set a goal of overtaking the Nasdaq market within five years in terms of the number of listings of mainland Chinese biotechnology firms.
Hong Kong plans to overtake Nasdaq as listing destination of choice for Chinese biotech firms
He expressed confidence that big name companies reportedly seeking listings, including Chinese mobile phone maker Xiaomi, oil company Saudi Aramco and Chinese online payment firm Ant Financial, would list in Hong Kong, and did not see plans by China to create China depositary receipts (CDRs), similar to American depositary receipts, to lure tech firms home as a threat to Hong Kong.
“According to my understanding, Ant Financial does not have a weighted voting right structure, so it is qualified to list A shares in China and H shares in Hong Kong,” he added.
Ant Financial is an affiliate of Chinese e-commerce giant Alibaba, which decided in 2014 to list in the US and not Hong Kong, where its dual-class share structure was not accepted at the time. The loss of the listing – worth US$25 billion – was the spark for debate in Hong Kong over listing rules.
Li said Alibaba could now apply for a secondary listing in Hong Kong, something the company’s founder, Jack Ma Yun, said in January he would “seriously consider”.
Jack Ma to consider listing Alibaba on Hong Kong stock exchange
Even if Alibaba opted for a CDR listing in mainland China, it would be an advantage if it also listed in Hong Kong, Li said, because Chinese investors could trade the physical stock directly via the Stock Connect scheme that links mainland and Hong Kong bourses, while international investors could arbitrage on the price differences between the US and Hong Kong listed stocks.
Li also saw Xiaomi as taking a similar tack, listing in Hong Kong as well issuing CDRs in mainland China.
Wall Street cheers Hong Kong’s IPO rules revamp but sees New York’s dominance unthreatened
Full Article....
https://www.google.com/amp/m.scmp.com/busines...les%3famp=
Aloha
(6)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼